OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, Rudolf M. Huber et al.|Journal of Thoracic Oncology|2017Cited by 20
P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Egbert F. Smit et al.|Journal of Thoracic Oncology|2017Cited by 3